ArticlePloS one2025
Green synthesis of zinc oxide nanoparticles using ethanolic leaf extract of Olea europaea and its in vitro evaluation on MDA-MB-231 cancer cell lines, antibacterial and antioxidant activities.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are about 1.4 million cases of breast cancer in women that are diagnosed annually worldwide. Treatments to downregulate these tumor cells include surgery, immunotherapy, and chemotherapy. This study evaluates the synthesis of zinc oxide nanoparticles (ZnONPs) and Olea europaea (O. europaea) and its characterization, antioxidant, antimicrobial, and cytotoxic effects. The Gas Chromatography-Mass Spectrometry analysis indicated bioactive compounds that are present in O. europaea, such as Apigenin, Oleoside, Hydroxytyrosol, Rutin, Oleuropein aglycone, Tyrosol, and Oleuropein. The Ultraviolet visible spectroscopy analysis indicated the spectrum with peaks of 238 nm, 282 nm, and 313 nm. The zeta sizing analysis showed a size of 86 nm with a charge of -12.64 mV, X-RAY Diffraction (XRD), which shows the crystalline structure of the material, and the Fourier Transform Infrared Spectrophotometer (FTIR), indicating the chemical bond, molecular composition, and the functional group. Scanning Electron Microscopy (SEM) and SEM-EDS (Energy Dispersive X-ray analysis were done to determine surface morphology and elemental composition. An antioxidant activity assay was performed using diphenylpicryl hydrazine (DPPH) for free radical scavenging activity. The antibacterial inhibition assay was performed, and the results obtained were gentamycin 42.55 mm, Pseudomonas aeruginosa (P. aeruginosa) 29.22 mm, Escherichia coli (E. coli) 12.55 mm, Staphylococcus aureus (S. aureus) 16.40 mm, and Bacillus cereus (B. cereus) 8.44 mm. Cytotoxicity assay was performed on Dulbecco's Modified Eagle Medium DMEM-grown MDA-MB-231 cells with varying dosage concentrations. The result showed that after 24 hours of treatment, cells were reduced to 60%, and after 48 hours of incubation, there was a 47% effect of ZnONPs. ZnO nanoparticle activity caused the MDA-MB-231 breast cancer cells to shrink, aggregate, deform, and proliferate more slowly. This research showed the medicinal potency of O. europaea.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.